<DOC>
	<DOCNO>NCT02414854</DOCNO>
	<brief_summary>Primary Objective : To evaluate efficacy dupilumab ( SAR231893 [ REGN668 ] ) patient persistent asthma . Secondary Objectives : To evaluate safety tolerability dupilumab . To evaluate effect dupilumab improve patient-reported outcome include health-related quality life . To evaluate dupilumab systemic exposure incidence antidrug antibody .</brief_summary>
	<brief_title>Evaluation Dupilumab Patients With Persistent Asthma ( Liberty Asthma Quest )</brief_title>
	<detailed_description>The total duration study period patient 67 69 week , include screen period 3 5 week , treatment period 52 week , posttreatment period 12 week .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Inclusion criterion : Adults adolescent patient physician diagnosis asthma ≥12 month , base Global Initiative Asthma ( GINA ) 2014 Guidelines follow criterion : Existing treatment medium high dose ICS ( ≥250 mcg fluticasone propionate twice daily equipotent ICS daily dosage maximum 2000 mcg/day fluticasone propionate equivalent ) combination second controller ( eg , longacting beta agonist , leukotriene receptor antagonist ) least 3 month stable dose ≥1 month prior Visit 1 . Note Japan : subject age 18 year old , ICS must ≥200 mcg fluticasone propionate twice daily equivalent ; subject age 12 17 year , ICS must ≥100 mcg fluticasone propionate twice daily equivalent ) . Patients require third controller asthma consider eligible study , also use least 3 month stable dose ≥1 month prior Visit 1 . Exclusion criterion : Patients &lt; 12 year age minimum legal age adolescent country investigative site , whichever high ( For country local regulation permit enrollment adult , subject recruitment restrict ≥18 year age ) . Weight le 30 kilogram . Chronic obstructive pulmonary disease lung disease ( eg , idiopathic pulmonary fibrosis , ChurgStrauss Syndrome , etc ) may impair lung function . A subject experience severe asthma exacerbation ( define deterioration asthma result emergency treatment , hospitalization due asthma , treatment systemic steroid time 1 month prior Screening Visit include Baseline Visit ) . Evidence lung disease ( ) asthma , either clinical evidence imaging ( Chest Xray , CT , MRI ) within 12 month Visit 1 screen visit , per local standard care . Note Japan : According request health authority , chest Xray perform screen visit chest imaging ( Chest Xray , CT , MRI ) available within 3 month prior screen exclude patient suspect active untreated latent tuberculosis . Current smoker cessation smoking within 6 month prior Visit 1 . Previous smoker smoke history &gt; 10 packyears . Comorbid disease might interfere evaluation Investigational Medicinal Product . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>